WONBIOGEN CO., LTD. Financials Wonbiogen Co., Ltd.
Equities
A307280
KR7307280008
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,680 KRW | -2.50% |
|
-6.72% | -1.29% |
| 2023 | Wonbiogen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2022 | Tranche Update on Wonbiogen Co., Ltd.'s Equity Buyback Plan announced on May 16, 2022. | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 74,002 | 58,397 | 60,375 |
| Enterprise Value (EV) 1 | 68,333 | 59,026 | 59,136 |
| P/E ratio | -96.7 x | 18.8 x | 11.7 x |
| Yield | - | 0.6% | 1.18% |
| Capitalization / Revenue | 4.18 x | 2.18 x | 2.04 x |
| EV / Revenue | 3.86 x | 2.21 x | 2 x |
| EV / EBITDA | 23.4 x | 9.45 x | 6.87 x |
| EV / FCF | -4,112,924 x | -14,723,587 x | 45,719,441 x |
| FCF Yield | -0% | -0% | 0% |
| Price to Book | 2.77 x | 2.17 x | 1.87 x |
| Nbr of stocks (in thousands) | 36,454 | 34,969 | 35,473 |
| Reference price 2 | 2,030 | 1,670 | 1,702 |
| Announcement Date | 18/03/22 | 21/03/23 | 20/03/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales 1 | 12,018 | 17,721 | 26,748 | 29,615 |
| EBITDA 1 | 3,223 | 2,921 | 6,249 | 8,607 |
| EBIT 1 | 2,492 | 2,040 | 5,050 | 7,038 |
| Operating Margin | 20.74% | 11.51% | 18.88% | 23.76% |
| Earnings before Tax (EBT) 1 | -11,282 | -795.5 | 3,667 | 7,157 |
| Net income 1 | -11,662 | -716.2 | 3,206 | 5,497 |
| Net margin | -97.04% | -4.04% | 11.99% | 18.56% |
| EPS 2 | -503.0 | -21.00 | 89.00 | 145.0 |
| Free Cash Flow | - | -16,614 | -4,009 | 1,293 |
| FCF margin | - | -93.76% | -14.99% | 4.37% |
| FCF Conversion (EBITDA) | - | - | - | 15.03% |
| FCF Conversion (Net income) | - | - | - | 23.53% |
| Dividend per Share | - | - | 10.00 | 20.00 |
| Announcement Date | 18/03/22 | 18/03/22 | 21/03/23 | 20/03/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 6.843 | 6.068 | 7.738 | 7.497 | 6.951 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | 1.695 | 0.9153 | 1.824 | 1.957 | 1.62 |
| Operating Margin | - | 24.77% | 15.09% | 23.58% | 26.1% | 23.3% |
| Earnings before Tax (EBT) 1 | - | 1.456 | 0.3525 | 1.894 | 2.749 | 0.7801 |
| Net income 1 | 0.8117 | 1.502 | -0.0121 | 1.437 | 2.126 | 0.5762 |
| Net margin | - | 21.95% | -0.2% | 18.57% | 28.36% | 8.29% |
| EPS | 22.00 | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 22/08/22 | 16/11/22 | 08/02/23 | 10/05/23 | 10/08/23 | 08/11/23 |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | 1,437 | - | 628 | - |
| Net Cash position 1 | - | 5,669 | - | 1,238 |
| Leverage (Debt/EBITDA) | 0.4459 x | - | 0.1006 x | - |
| Free Cash Flow | - | -16,614 | -4,009 | 1,293 |
| ROE (net income / shareholders' equity) | - | -5.11% | 12.3% | 20.1% |
| ROA (Net income/ Total Assets) | - | 4.45% | 8.2% | 10.7% |
| Assets 1 | - | -16,101 | 39,094 | 51,139 |
| Book Value Per Share 2 | -921.0 | 733.0 | 768.0 | 908.0 |
| Cash Flow per Share 2 | 303.0 | 210.0 | 92.30 | 85.60 |
| Capex 1 | 679 | 2,336 | 6,494 | 1,646 |
| Capex / Sales | 5.65% | 13.18% | 24.28% | 5.56% |
| Announcement Date | 18/03/22 | 18/03/22 | 21/03/23 | 20/03/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -1.29% | 44.04M | |
| +10.10% | 27.85B | |
| -30.75% | 3.09B | |
| +35.19% | 2.66B | |
| -18.85% | 2.44B | |
| +6.85% | 2.24B | |
| +33.33% | 2.05B | |
| -4.71% | 2.02B | |
| +34.05% | 1.35B | |
| +3.25% | 1.33B |
- Stock Market
- Equities
- A307280 Stock
- Financials Wonbiogen Co., Ltd.
